NeuroMetrix Inc.
NURO
NSC
Sector: Healthcare
Industry: Medical Instruments & Supplies
3.54
USD
-0.01
(-0.28%)
Optionable: No Market Cap: 24 M 90-day average vol: 1,675,461
Previous close: 3.55 Open: 3.555 Bid: 3.57 Ask: 3.57
52 week range
2.70 19.74
Last updated: Sunday 14th August 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 2.87 |
Price per Book TTM ($) | 1.14 |
PE Ratio (TTM) | -6.20 |
Book Value per Share ($) | 3.28 |
5 Year PE Range-11 |
Returns
7 Day Return | -5.09% | |
1 Month Return | -7.09% | |
3 Month Return | 6.95% | |
1 Year Return | -70.98% | |
3 Year Return | 1.26% | |
5 Year Return | -80.55% | |
YTD Return | -29.48% |
Risk
Custom Beta One Year | 1.39 |
Custom Beta Three Years | 1.05 |
Beneish M Score | -2.60 |
Altman Z Score | -1.93 |
Financial Health
Technicals
RSI (14 Day) | 48.57 |
14 Day SMA ($) | 3.55 |
14 Day EMA ($) | 3.58 |
Money Flow Index | 84.52 |
Average True Range | 0.31 |
50 Day SMA ($) | 3.64 |
200 Day SMA ($) | 4.64 |
ADX | 58.63 |
MACD | -0.02 |
Growth
Free Cash Flow QoQ Growth | 43.66% |
Free Cash Flow YoY Growth | 6.16% |
Revenue YoY Growth | 11.87% |
EPS QoQ Growth | -6.67% |
Revenue QoQ Growth | 26.49% |
EPS YoY Growth | -34.78% |
Profitability
Chart
News
NeuroMetrix's Quell Neuromodulator Will Be Tested In Long COVID-19 Syndrome
Yahoo Finance 2/24/2022
NeuroMetrix Reports that Quell® Wearable Neuromodulator to be Evaluated in Post-Acute COVID-19 Syndrome
Yahoo Finance 2/24/2022
NeuroMetrix, Inc.'s (NURO) CEO Dr. Shai Gozani On Q4 2021 Results - Earnings Call Transcript
Seeking Alpha 1/27/2022
NeuroMetrix reports Q4 results
Seeking Alpha 1/27/2022
NeuroMetrix Reports Q4 and Full Year 2021 Financial Results
Yahoo Finance 1/27/2022
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2021 Financial Results Conference Call
Yahoo Finance 1/20/2022
NURO Stock: Why NeuroMetrix Investors Are Feeling No Pain Today
Yahoo Finance 1/18/2022
NeuroMetrix surges on FDA Breakthrough Designation for neurostimulation technology
Seeking Alpha 1/18/2022
NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation Technology
Yahoo Finance 1/18/2022
NeuroMetrix Up 31.5% on FDA Breakthrough Device Designation
Yahoo Finance 1/18/2022
NeuroMetrix Names Strategic Growth Executive, Brandi Damkier, as Vice President, Clinical Partnerships
Yahoo Finance 1/10/2022
NeuroMetrix to Present at H.C. Wainwright BioConnect Conference 2022
Yahoo Finance 1/5/2022
NeuroMetrix shares fall after wider Q3 net loss
Seeking Alpha 10/21/2021
NeuroMetrix, Inc. (NURO) CEO Dr. Shai Gozani on Q3 2021 Results - Earnings Call Transcript
Seeking Alpha 10/21/2021
NeuroMetrix reports Q3 results
Seeking Alpha 10/21/2021
NeuroMetrix Reports Q3 2021 Financial Results
Yahoo Finance 10/21/2021
NeuroMetrix Names Strategic Growth Executive, Susan M. Bell, RN, BN, as Senior Vice President of Population Health & Value Based Care
Yahoo Finance 10/20/2021
Those who invested in NeuroMetrix (NASDAQ:NURO) a year ago are up 453%
Yahoo Finance 10/20/2021
NeuroMetrix, Inc. Announces Date for Third Quarter 2021 Financial Results Conference Call
Yahoo Finance 10/14/2021
Trend Analysis & Forecast
Read more on this trend analysis & forecast here - uptrenddowntrend.com
Trendlast: 46.337
Financials
NURO Income Statement
Annual
| Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 8 M | 5 M | 6 M | 7 M | 12 M | 17 M | 16 M | 9 M | 7 M | 8 M |
| Cost of sales | 3 M | 2 M | 2 M | 4 M | 7 M | 10 M | 9 M | 7 M | 2 M | 2 M |
| Gross operating profit | 4 M | 3 M | 3 M | 3 M | 5 M | 7 M | 7 M | 2 M | 5 M | 6 M |
| Selling Gen & administrative expense | 10 M | 7 M | 8 M | 13 M | 16 M | 16 M | 15 M | 11 M | 5 M | 6 M |
| Research & development expense | 4 M | 3 M | 4 M | 4 M | 4 M | 3 M | 5 M | 3 M | 2 M | 3 M |
| Operating income | -10 M | -7 M | -9 M | -13 M | -15 M | -13 M | -12 M | -12 M | -2 M | -2 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | 0 | -665963 | 999221 | 4 M | 275662 | 223365 | 12 M | 8 M | 2709 | 3150 |
| Pre-tax Income (EBT) | -10 M | -8 M | -8 M | -9 M | -15 M | -13 M | 23605 | -4 M | -2 M | -2 M |
| Income taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from total operations | -10 M | -8 M | -8 M | -9 M | -15 M | -13 M | 23605 | -4 M | -2 M | -2 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -10 M | -8 M | -8 M | -9 M | -15 M | -13 M | 23605 | -4 M | -2 M | -2 M |
| Preferred dividends | N/A | 766872 | 3 M | 12 M | 20 M | 7 M | N/A | N/A | N/A | N/A |
| Net income available for common | -10 M | -9 M | -11 M | -21 M | -35 M | -20 M | 23605 | -4 M | -2 M | -2 M |
| Depreciation | 297097 | 150663 | 145100 | 222592 | 251327 | 262334 | 169712 | 124012 | 89954 | 76378 |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | -10 M | -7 M | -9 M | -13 M | -15 M | -13 M | -12 M | -11 M | -2 M | -2 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | -1670.4 | -982.4 | -492.8 | -620 | -582.4 | -115.98 | 0.03 | -3.9 | -0.69 | -0.45 |
| Diluted EPS total | -1670.4 | -982.4 | -492.8 | -620 | -582.4 | -115.98 | 0.02 | -3.9 | -0.69 | -0.45 |
Top MarketXLS Rank stocks
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started today
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!